Boehringer Ingelheim and GoodRx, a prescription savings platform, have announced a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer's biosimilar to Humira (adalimumab), at a low cash price available exclusively on GoodRx.
This program aims to address access and affordability in one of the largest therapeutic categories with a high cost burden for patients.
Adalimumab-adbm is an FDA-approved interchangeable biosimilar to Humira. The citrate-free, injectable medication is used to treat or reduce the signs and symptoms of certain autoimmune conditions, such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and ulcerative colitis. By working together to offer consumers a low cash price, the companies are broadening access and affordability for this drug. Now, anyone with a valid prescription, regardless of insurance status, can use GoodRx to purchase Adalimumab-adbm at over 70,000 retail pharmacies nationwide.
"Patients with certain chronic inflammatory diseases who do not have insurance or are underinsured may not be able to afford essential biologic medicines, including biosimilars, to treat their disease," said Chris Marsh, Senior Vice President of Value and Access at Boehringer Ingelheim. "Partnering with GoodRx to offer our biosimilar Adalimumab-adbm at a low price to these patients helps us deliver on our commitment to lowering financial barriers and improving access to critical treatments."
"For over a decade, GoodRx has been working to help reduce the costs of medications for patients, and we recognize the critical need for ensuring biosimilars are affordable to all," said Dorothy Gemmell, Chief Commercial Officer at GoodRx. "We're excited to leverage the reach and scale of the GoodRx platform to help address this access gap and make Adalimumab-adbm more accessible to patients."
Earlier this year, Boehringer Ingelheim also entered an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm in the U.S.
